Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | Suppliers

Almac Group – Partnering to Advance Human Health News

Almac Group – Partnering to Advance Human Health

Lismore Comprehensive Represent Northern Ireland in Young Enterprise UK final A group of innovative pupils from Lismore Comprehensive is representing Northern Ireland in London this week as they pitch their novel product in the UK final of the Young Enterprise Company of the Year competition.
View press release
High-Demand IT Skills being Developed at Innoative Summer Camp Novosco Cloud Camp in partnership with Almac Group returns
View press release
“Portadown Gets Active” A scheme to support local children and end holiday hunger Children in Northern Ireland has just launched a scheme to support local children in Portadown. The programme is being delivered in partnership with the community and voluntary sector, statutory agencies, local schools and local government with additional support from Craigavon based Almac Group.
View press release
Almac Group Announce US Workshops Targeting EU Product Launch Best Practices Almac Group, the global contract development and manufacturing organisation, is delighted to announce two free, one-day exclusive knowledge sharing events titled "Almac Product Launch Workshop" on Tuesday, September 26th at the Andaz Hotel in San Diego, CA and on Thursday, September 28th at the DoubleTree by Hilton Hotel, Downtown Boston, MA.
View press release
Almac Discovery is Granted Orphan Drug Designation for ALM201 Programme in Ovarian Cancer Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug candidate ALM201 in the treatment of ovarian cancer.
View press release
Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA, a Switzerland based speciality pharma company, today announced a collaboration to pursue the development of Almac Discovery’s Wee-1 kinase inhibitor programme.
View press release
Almac Group Awarded U.S. Patent for Ground-breaking “DDRD” Assay Almac Group’s Diagnostics business unit announced today it was granted intellectual property protection for its DNA Damage Response Deficiency (DDRD) assay.
View press release
Almac Discovery Announce key Wee-1 kinase patent approval Inhibitors of Wee-1 kinase, cell cycle regulator, have potential for clinical utility across a broad range of cancer indications
View press release
Almac Group Announces Publication of Prostate Cancer Metastatic Assay Validation Almac Group’s Diagnostics business unit today announced the Journal of European Urology has published results relating to its Prostate Cancer Metastatic Assay. The publication demonstrates the assay can be used to analyse primary prostate cancer FFPE samples to identify a molecular subgroup with a high risk of developing distant metastases. The assay therefore has the potential to guide the choice of therapy for patients presenting with primary prostate cancer.
View press release
Almac Diagnostics and EORTC Establish Collaboration for Tumour Molecular Profiling Partnership to support the discovery and development of novel biomarkers, enabling personalised medicine
View press release
RCSI and Almac Discovery Enter Research Collaboration to Target Therapy-Resistant Cancer Tumours Research has potential to improve 20 per cent survival rate in ovarian cancer
View press release
Almac Group Launches Next Generation Temperature Management Software Innovative ‘TempEZ™’ solution offers unrivalled end-to-end drug product visibility
View press release
Almac Group Announces Further Global Expansion as it Secures New Premises in Republic of Ireland Craigavon based global contract pharmaceutical development and manufacturing organisation, Almac Group, has secured new premises in Dundalk, County Louth to support its ongoing global expansion plans in response to increased client demand.
View press release
Almac Group Launches Almac Clinical University A first-in-industry, web-based training & education platform designed to enhance, educate, and strengthen connections with valued clients and industry professionals across the globe.
View press release
Almac Group Collaborates with Exostar to Extend Clinical Trials Identity Management eClinical Application Users Benefit from Single Sign-On Expediency & Enhanced Security
View press release
Almac Group Announces Strategic Partnership with inVentiv Health Almac Clinical Technologies, part of the Almac Group, the world's largest privately-held contract pharmaceutical development and manufacturing organisation, today announced the formation of a strategic partnership with inVentiv Health, a leading biopharma outsourcing company combining a leading CRO and the industry's only Contract Commercial Organization (CCO). The partnership presents an opportunity for both organisations to provide clients and sites with streamlined access to best-in-class clinical trial Interactive Response Technology (IRT) solutions.
View press release
Almac Group Team Up with Irish American Business Chamber & Network for Life Sciences Forum In Association with the British American Business Council of Greater Philadelphia
View press release
Almac Group Expands Commercial Capabilities to Meet Industry Demand for Paediatric Formulations Almac Group, the global contract development and manufacturing organisation, is pleased to announce that it has expanded its MHRA/FDA approved UK commercial packaging facility with the acquisition of a stick sachet packaging line from Merz
View press release
Almac Group Expands Commercial Capabilities to Meet Industry Demand for Paediatric Formulations Almac Group, the global contract development and manufacturing organisation, is pleased to announce that it has expanded its MHRA/FDA approved UK commercial packaging facility with the acquisition of a stick sachet packaging line from Merz.
View press release
Almac Group Wins Prestigious CIM Award Almac Group, the global contract development and manufacturing organisation, is delighted to have won the coveted Chartered Institute of Marketing (CIM) Marketing in Life Sciences award.
View press release
Wolf Administration Announces 312 New Jobs with Expansion of Almac Group Facilities in Montgomery County As part of a stop on his ‘Jobs that Pay’ tour, Department of Community and Economic Development Secretary Dennis Davin announced that Almac Group, Inc., a global contract pharmaceutical development and manufacturing organization, will expand operations at its existing U.S. headquarters in Souderton, Montgomery County, and double its physical presence in nearby Lansdale, Montgomery County. The company’s expansion will create 312 new jobs over the next three years.
View press release
Almac Group Announce £27 million Global Expansion Almac Group, the global contract pharmaceutical development and manufacturing organisation is excited to announce ambitious plans to expand its operations in Europe and North America increasing its global headcount to reach 5,000 by 2017
View press release
Almac Group’s Temperature Management Software Solution Receives Innovation Award Almac Group, the global contract development and manufacturing organisation is delighted to announce that its temperature management software solution, TempEZ™, has received the award for Innovation from IT services company, Version 1, during their ‘Evolving the Digital Enterprise Expo’ at the Royal College of Physicians, Dublin, Ireland
View press release
Almac Group Wins Prestigious Research and Development Award Almac Group, the global contract development and manufacturing organisation is delighted to have won the coveted Research and Development achievement award at this years’ Pharma Industry Awards.
View press release
Almac's Colon Cancer Recurrence Assay in Journal of Clinical Oncology Almac Publish Second Validation of Stage II Colon Cancer Recurrence Assay in the Journal of Clinical Oncology.
View press release
Almac Group Supports Amicus Therapeutics' Commercial Orphan Drug Product Almac Group's Integrated Development to Commercialisation Services Support Amicus Therapeutics' First Commercial Orphan Drug Product.
View press release
Almac Group’s Integrated CMC Services Support US Approval of Wellstat Therapeutics’ First Commercial Orphan Drug Product Almac Group, the global contract development and manufacturing organisation, wishes to congratulate its long term client partner Wellstat Therapeutics on the commercial approval of their first orphan drug product XURIDEN™ (uridine triacetate). XURIDEN has been developed as a treatment for the rare disease Hereditary Orotic Aciduria (HOA).
View press release
Almac Group expands Asia Pacific Presence with New Regional Headquarters and Clinical Trial Supply Facility in Singapore Due to the overwhelming success experienced since the launch of its “Direct to Patient” shipping service for clinical trials throughout US and Canada in October last year, Almac has announced the expansion of this innovative service to EU countries.
View press release
Almac Discovery Announce Ubiquitin Specific Protease Collaboration with Genetech Almac Discovery, a biopharmaceutical company focused on identifying and developing innovative therapeutics for the treatment of cancer, today announced a Research and Licensing agreement with Genentech, a member of the Roche Group (SIX:RO, ROG; OTCQX: RHHBY) to discover and develop small molecule inhibitors of a ubiquitin specific protease (USP) target.
View press release
Almac Group Names UK Trade & Investment Winner in Final of the European Business Awards 2014/15 Almac Group was last night named the winner of ‘The UKTI Award for Innovation’ in the final of this year’s European Business Awards, sponsored by RSM, at an exclusive awards ceremony held in London attended by prominent businesses leaders, European ambassadors and political representatives from the EU.The win celebrates the end of a yearlong journey for Almac that began in spring 2014 when the European Business Awards engaged with over 24,000 businesses at the entry stage of the competition. After being named one of 709 National Champions from 33 countries in November, the company took part in the public vote, which generated 174,000 votes, a record-breaking year.
View press release